BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Закрыт

СекторЗдравоохранение

92.54 -0.88

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

92.18

Макс.

94.26

Ключевые показатели

By Trading Economics

Доход

-2.3B

499M

Продажи

-6.5B

7.6B

P/E

Средняя по отрасли

20.663

57.333

Прибыль на акцию

1.31

Дивидендная доходность

4.32

Рентабельность продаж

6.539

Сотрудники

82,878

EBITDA

-3.7B

563M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+22.28% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

4.32%

2.63%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-20B

111B

Предыдущая цена открытия

93.42

Предыдущая цена закрытия

92.54

Техническая оценка

By Trading Central

Уверенность

Neutral Evidence

Sanofi SA График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2025 г., 08:52 UTC

Отчет

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 апр. 2025 г., 05:44 UTC

Отчет

Sanofi Sales, Profit Beat Expectations

9 апр. 2025 г., 06:00 UTC

Приобретения, слияния, поглощения

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 мар. 2025 г., 06:43 UTC

Приобретения, слияния, поглощения

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 апр. 2025 г., 12:54 UTC

Обсуждения рынка
Отчет

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 апр. 2025 г., 10:06 UTC

Обсуждения рынка
Отчет

Sanofi Starts the Year Strong -- Market Talk

10 апр. 2025 г., 12:06 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 апр. 2025 г., 09:10 UTC

Популярные акции

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 апр. 2025 г., 10:49 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 апр. 2025 г., 08:19 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 апр. 2025 г., 06:59 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 апр. 2025 г., 06:46 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 апр. 2025 г., 09:07 UTC

Популярные акции

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 апр. 2025 г., 07:51 UTC

Обсуждения рынка

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 апр. 2025 г., 13:44 UTC

Обсуждения рынка

Santander Push Into Canada on the Cards -- Market Talk

2 апр. 2025 г., 09:27 UTC

Популярные акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 мар. 2025 г., 06:19 UTC

Обсуждения рынка
Отчет

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 мар. 2025 г., 10:08 UTC

Обсуждения рынка

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 мар. 2025 г., 09:00 UTC

Главные новости

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 мар. 2025 г., 06:05 UTC

Приобретения, слияния, поглощения

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 мар. 2025 г., 06:05 UTC

Приобретения, слияния, поглощения

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 мар. 2025 г., 06:04 UTC

Приобретения, слияния, поглощения

Sanofi to Pay $600M Upfront

20 мар. 2025 г., 06:02 UTC

Приобретения, слияния, поглощения

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 мар. 2025 г., 06:00 UTC

Приобретения, слияния, поглощения

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 мар. 2025 г., 09:33 UTC

Популярные акции

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 мар. 2025 г., 23:00 UTC

Главные новости

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 мар. 2025 г., 09:50 UTC

Отчет

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 мар. 2025 г., 09:49 UTC

Отчет

Santander Increased 2024 Cash Payments by 19%

24 февр. 2025 г., 08:56 UTC

Обсуждения рынка
Отчет

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 февр. 2025 г., 08:30 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Сравнение c конкурентами

Изменение цены

Sanofi SA Прогноз

Целевая цена

By TipRanks

22.28% рост

Прогноз на 12 месяцев

Средняя 114.144 EUR  22.28%

Максимум 127 EUR

Минимум 83.729 EUR

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Sanofi SA на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

14 ratings

10

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

91.62 / 93.4Поддержка и Сопротивление

Краткосрочная

Neutral Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Strong Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.